IHC Marker-CD13 Test: Booking, Price, and Results
About IHC Marker-CD13 Test: Booking, Price, and Results
| Field | Value |
|---|---|
| Also Known As | CD13, Aminopeptidase N (APN), ANPEP (Alanyl Aminopeptidase, Membrane), Myeloid Antigen CD13, gp150 |
| Sample Type | Tissue biopsy (formalin-fixed paraffin-embedded block) |
| Fasting Required | No |
| Report Time | 3 days |
| Recommended For | All genders and ages; typically ordered when investigating suspected leukaemia, hepatocellular carcinoma, meningioma, or other tumours |
| Price | Starting at ₹1,920 |
What is an IHC Marker-CD13 Test?
The IHC marker-CD13 test is a specialised immunohistochemistry test that detects the presence and distribution of the CD13 protein in tissue samples. CD13, also called Aminopeptidase N (APN), is a protein normally found on certain blood and tissue cells. Doctors order this test to help identify and classify specific cancers, including leukaemias and solid tumours. The test uses a formalin-fixed paraffin-embedded (FFPE) tissue block, which is prepared from a biopsy sample.
What Does an IHC Marker-CD13 Test Measure?
This test detects and evaluates the CD13 protein, also known as ANPEP (Alanyl Aminopeptidase, Membrane), in tumour tissue. CD13 is a zinc-binding enzyme on the cell surface that plays a role in peptide breakdown, cell growth, and immune recognition. Its presence, intensity, and pattern of staining help a pathologist identify the type and origin of abnormal cells.
The two key parameters assessed are listed below.
| Parameter | Normal Range | Interpretation |
|---|---|---|
| CD13 Expression | Positive or Negative | Qualitative assessment based on staining pattern and intensity |
| Staining Pattern | Score 0 to 2 (or percentage-based) | Score 0 = no expression; Score 1 = expression in 1 to 40% of tumour cells; Score 2 = expression in more than 40% of tumour cells |
Why is an IHC Marker - CD13 Test Done?
This test is ordered when a doctor suspects certain cancers or needs to classify abnormal cells found during a biopsy. It is part of a broader panel of markers used in tumour diagnosis.
Common Symptoms That May Require This Test
The following symptoms may prompt a doctor to order this test.
- Unexplained and persistent fatigue
- Recurrent or frequent infections
- Unexplained weight loss
- Abnormal bleeding or bruising
- Bone pain or tenderness
- Swollen lymph nodes
- Liver masses or nodules found on imaging
Conditions This Test Can Help Detect
This test may assist in identifying several serious conditions.
- Acute myeloid leukaemia (AML), where the myeloid antigen CD13 is among the most frequently expressed markers
- Chronic myeloid leukaemia (CML) in myeloid blast crisis
- A subset of lymphoid leukaemias
- Hepatocellular carcinoma (liver cancer), where CD13 shows a characteristic distribution pattern
- Meningiomas, which are tumours arising from the membranes covering the brain and spinal cord
- Soft tissue sarcomas
How to Prepare and What to Expect
No fasting or complex preparation is required for this test. However, some practical steps will help ensure a smooth experience.
Do You Need to Fast?
No fasting is required. This test is performed on a tissue sample collected via biopsy, not on blood or urine.
Practical Tips Before Your Test
The following tips will help you prepare.
- Bring a detailed clinical history including your symptoms, previous test results, and family history, as this is required for the test.
- Carry any previous biopsy reports and imaging studies, such as ultrasound or MRI scans, if available.
- Inform your doctor about any medications you are currently taking or any known allergies.
- Discuss the biopsy procedure in detail with your doctor beforehand, so you know what to expect.
- Ensure the tissue sample is fixed in 10% neutral-buffered formalin within the recommended window (12 to 24 hours, not exceeding 48 hours), as advised by your doctor or the collecting facility.
Step-by-Step Procedure
Here is a brief overview of what happens during the IHC marker - CD13 test process.
- A tissue sample is collected from the suspected tumour site through a biopsy, performed by a qualified doctor under local or general anaesthesia as appropriate.
- The collected tissue is fixed in formalin and embedded in a paraffin block to preserve it for laboratory analysis.
- Thin sections are cut from the paraffin block and mounted on glass slides.
- The slides undergo antigen retrieval, a standard step that exposes the CD13 protein for accurate detection.
- Specific antibodies are applied to the tissue sections to selectively highlight CD13 protein wherever it is present.
- A qualified pathologist examines the stained slides under a microscope, assessing the presence, intensity, and pattern of CD13 expression, and prepares a detailed report.
Factors That Can Affect Accuracy
Certain factors may influence the reliability of results.
- Delays or errors in tissue fixation after biopsy collection
- Sample processing timing and technique
- Prior chemotherapy or radiation therapy affecting tissue appearance
- Quality of antibodies used in the laboratory
- Overall laboratory technique and pathologist expertise
Understanding Your IHC Marker-CD13 Test Results
Results from this test are qualitative, meaning they describe the presence or absence and the pattern of CD13 protein staining, rather than a numerical value. A qualified pathologist will analyse the stained sections and issue a report. Your treating doctor or oncologist will then interpret these findings alongside other tests, imaging, and your clinical history.
| Parameter | Finding | Interpretation |
|---|---|---|
| CD13 Expression | Positive | CD13 protein detected in tumour cells; may suggest myeloid lineage, hepatocellular carcinoma, meningioma, or soft tissue sarcoma depending on clinical context |
| CD13 Expression | Negative | CD13 protein not detected; may support diagnoses such as schwannoma or solitary fibrous tumour |
| Staining Pattern | Canalicular (bile duct pattern) | Associated with hepatocellular carcinoma |
| Staining Pattern | Diffuse cytoplasmic or membranous | Seen in myeloid leukaemias and meningiomas |
These ranges are general guidelines. Your doctor will interpret your results based on your age, health history, and other factors. Always consult a qualified healthcare professional for personalised medical advice.
How to Maintain Healthy Levels
While the CD13 test is used for diagnosis rather than routine monitoring, the following general wellness habits support overall health.
- Attend regular health check-ups as recommended by your doctor, particularly if you have a family history of cancer.
- Report any unusual symptoms such as unexplained fatigue, persistent bruising, or new lumps promptly to your doctor.
- Follow a balanced diet and an active lifestyle to support immune function and overall wellbeing.
Lupin Diagnostics IHC Marker-CD13 Test Price
The IHC marker-CD13 test is priced starting at ₹1,920 at Lupin Diagnostics. This test requires a visit to a Lupin Diagnostics centre or affiliated collection point, as home collection is not available for this test.
| City | Approximate Price (₹) |
|---|---|
| BHOPAL | 1920 |
| CHENNAI | 1920 |
| HYDERABAD | 1920 |
| KOLKATA | 1920 |
| NAVI MUMBAI | 1920 |
| PUNE | 1920 |
Disclaimer: Prices are indicative and may vary by location. Please confirm the current price at the time of booking.
How to Book
Follow these steps to book the CD13 IHC marker test at Lupin Diagnostics.
- Select the test on the Lupin Diagnostics website.
- Choose your city and preferred centre location.
- Visit the centre at your scheduled time for sample collection or submission of your FFPE tissue block.
- Receive your report via email or WhatsApp within the stipulated turnaround time.
Frequently Asked Questions
CD13, also called Aminopeptidase N (APN), is a protein found on the surface of certain blood and tissue cells. It acts as an enzyme involved in peptide breakdown and immune recognition. It is tested to help identify and classify cancers such as leukaemia, liver cancer, and brain tumours.
The tissue sample is collected through a biopsy, where a small piece of tissue is surgically removed from the suspected tumour site. The method of biopsy depends on the location and nature of the suspected tumour. Your doctor will explain the procedure before it is carried out.
The IHC test itself is performed in the laboratory on tissue that has already been collected. Any discomfort comes from the biopsy procedure, which is typically done under local anaesthesia to minimise pain.
At Lupin Diagnostics, the report is delivered within 3 days. Turnaround time can vary based on the complexity of the case and whether additional markers are being tested alongside CD13.
No. The CD13 myeloid antigen test is one marker among several used in cancer diagnosis. It is always interpreted alongside other immunohistochemistry markers, clinical findings, blood tests, and imaging results by a qualified pathologist or oncologist.
No. The IHC marker - CD13 test requires a tissue biopsy sample collected by a qualified medical professional in a clinical or hospital setting. The FFPE block must be submitted directly to a Lupin Diagnostics centre.
A positive CD13 result means the protein was detected in your tissue sample. This finding, along with other test results and clinical information, will help your doctor determine the diagnosis. Your oncologist or treating doctor will guide you on the next steps.
IHC Marker-CD13 Test: Booking, Price, and Results
